US Press releases
FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma
March 1, 2021
—U.S. Commercial Launch Underway—
Change Language
March 1, 2021
—U.S. Commercial Launch Underway—